ERBB2 and non-small cell lung carcinoma: In a phase II study, pyrotinib, an irreversible pan-HER receptor TKI with activity against EGFR/HER1 and HER2, showed activity against HER2 mutant NSCLC and resulted in an ORR of 53.3% and a median PFS of 6.4 months (28).